Novo Nordisk has a dominant position in diabetes and weight-loss drugs, strong financial growth outlook, and great potential. Click to read why NVO is a Strong Buy.

Pharma giant Novo Nordisk, the company behind Wegovy and Ozempic, expects to launch six products in the next five years. Leading the pack of new drugs will be CagriSema.

CagriSema combines semaglutide, the active ingredient in Wegovy, with a molecule that mimics a pancreatic hormone.

The drug Ozempic, prescribed for patients with type 2 diabetes, is the latest trend for weight loss. Its popularity is high as it has been shown to be effective against obesity, bu ...

Lee Herring, 31, weighed 351 pounds and wore a size 5XL at his heaviest, when he would gorge on chocolate, sweets, cream buns ...

A consultant, an artist, a model, and a former staffer to the Surgeon General walk into a wine bar to decide what’s in and ...

The former KFC marketing whiz is leading one of the hottest restaurant chains on the planet in Chili's, an old school sit-down eatery that was born in 1975. It's long claim to fame has been saucy ribs ...

Singer-songwriter Lizzo has always been open about her health journey, emphasizing self-love and balance. Today, she's hit her weight loss thanks to a combination of mindful eating, realistic ...

Scientists unveil groundbreaking research on BCL6 protein that could help Ozempic users maintain muscle while losing weight. Here's what you need to know ...

WASHINGTON (AP) — Robert F. Kennedy Jr.'s anti-vaccine advocacy is outside the mainstream. His previous statements on ...

Ozempic face is not a direct side effect of the drug itself but rather a consequence of fat loss, which can cause skin laxity ...

My parents are both retired medical professionals who are in their early 70s. My father has diabetes that he manages with medication, and he also has a history ...